We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sumitovant Biopharma announced Urovant Sciences has entered into an exclusive three-year distribution agreement with Sunovion to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.
Urovant Sciences announced the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product ...